Family Motivational Intervention in Schizophrenia

Motivational Interviewing and Interaction Skills Training for Carers to Change Cannabis Use in Young Adults With Recent-onset Schizophrenia: Randomised Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01167556

Acronym

FMI

Enrollment

147

Registered

2010-07-22

Start date

2006-03-31

Completion date

2011-02-28

Last updated

2010-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis, Schizophrenia

Keywords

Family intervention, Recent-onset schizophrenia, Motivational Interviewing, Cannabis use

Brief summary

Cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. Therefore, an Family Motivational Intervention (FMI) was developed to help parents to motivate their child with a diagnoses of recent-onset schizophrenia to reduce cannabis use. In a single-blind randomised clinical trail with 75 patients with the diagnosis of schizophrenia, parents will be assigned to either FMI or to routine care. Assessments will be conducted at baseline and at a 10- and 22-month follow-up. The study hypothesis is that FMI will be more effective than routine care in reducing (a) cannabis use in patients and (b) distress and sense of burden in parents.

Interventions

BEHAVIORALFamily Motivational Intervention

A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

16 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of schizophrenia or psychotic-related disorder * Onset of schizophrenia or related disorder within pervious the 10 years * Cannabis use at least 2 days per week in the 3 months prior to the assessment * Antipsychotic medication in prescribed or indicated * At least 10 hours of contact with the parents each week in the last month

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Cannabis use in patients with a diagnosis of recent-onset schizophrenia	Baseline (before the start of the intervention)

Secondary

Measure	Time frame
Medication adherence in patients with a diagnosis of recent-onset schizophrenia	Baseline (before the start of the intervention)
Quality of life in patients with recent-onset schizophrenia	Baseline (before the start of the intervention)
Stress in parents due to caring for a child with recent-onset schizophrenia	Baseline (before the start of the intervention)
Expressed emotion in parents of patients with recent-onset schizophrenia	Baseline (before the start of the intervention)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026